Kirkland Advises Bain Capital and Cinven on Sale of STADA
Kirkland & Ellis advised Bain Capital and Cinven on the sale of a majority stake in STADA Arzneimittel AG (“STADA”) to CapVest Partners LLP. Bain Capital and Cinven will retain a minority stake in STADA.
The terms of the transaction have not been disclosed. The closing of the transaction is subject to customary regulatory approvals and is expected in H1 2026. Kirkland already advised Bain Capital and Cinven on the public takeover of STADA in 2017, the DPLTA in 2017, the delisting in 2018 as well as the squeeze-out in 2020.
Headquartered in Bad Vilbel, Germany, STADA is a leading manufacturer of high-quality pharmaceuticals. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. STADA sells its products in approximately 120 countries and has approximately 11,600 employees worldwide. In the financial year 2024, STADA achieved group revenues of more than €4 billion.
Read the transaction press release
The Kirkland team included transactional lawyers Benjamin Leyendecker, Philip Goj, Maximilian Liegl, Marcus Commandeur, Tamara Zehentbauer, Sabrina Seitz and Lionel Reich; capital markets lawyers Marwa Elborai and Georg Lorenz; debt finance lawyers Christopher Shield, Sam Sherwood, Jerome Hoyle and Aman Nath; and tax lawyers Michael Ehret and Emanuel Götz.
